This moderate increase in VEGF‐A in the eye is sufficient to promote AMD, as anti‐VEGF‐A antibodies inhibit the progression of neovascular AMD in a subset of patients or in experimental laser‐induced CNV (Campa et al, 2008; Group et al, 2011; Martin et al, 2011). Here, VEGFA is linked to age-related macular degeneration.